IPO registrations (S-1, F-1) · Registrants
GERON CORP
- SEC CIK
- 886744 · filings on EDGAR ↗
- Name on the registration
- GERON CORPORATION
- Former names
- GERON CORPORATION (1996–2005)
- Registration
- Form S-1, first filed 1996-06-12, last 1996-07-30; 1 initial registration, 4 amendments
- Outcome
- Final prospectus filed 1996-07-31
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- DE
- Business address
- 919 EAST HILLSDALE BOULEVARD, SUITE 250, Foster City, CA 94404
- EIN
- 75-2287752
- Ticker
- GERN (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- GERON CORP on the corporate pages
Offering terms
- Proposed price range
- $8.00–$10.00 per share (S-1/A filed 1996-07-30)
- Final price
- $8.00 per share, within the range (424B4 filed 1996-07-31, an initial public offering)
- Shares sold
- 2,000,000
- Gross proceeds
- $16,000,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol GERN
- Lead underwriters
- J.P. Morgan; Montgomery Securities (480,000 shares); Citigroup (480,000 shares)
- Syndicate
- Alex. Brown & Sons (100,000); Lehman Brothers (100,000); Morgan Stanley (100,000); Punk, Ziegel & Knoell, L.P (100,000)
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Business registration: FLORIDA GERON CORPORATION EXACT (EIN (EXACT, as the state registration reports it))
- Business registration: Geron Corporation Fuzzy (name and state)
- Business registration: Geron Corporation Fuzzy (name and state)
- Business registration: Geron Corporation Fuzzy (name and state)
- Business registration: Geron Corporation Fuzzy (name and state)
- Business registration: GERON CORPORATION Fuzzy (name and state)
- Business registration: GERON CORPORATION Fuzzy (name and state)
- Business registration: GERON CORPORATION Fuzzy (name and state)
- Business registration: GERON CORPORATION Fuzzy (name and state)
- Form 5500 plan sponsor: GERON CORPORATION EXACT (EIN (EXACT))
- Federal award recipient: GERON CORP Fuzzy (name and state)
- Lobbying client: GERON CORP Fuzzy (name and state)
- SEC filer: GERON CORP EXACT (CIK (EXACT))
Filings 6
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 1996-06-12 | S-1 | S-1 (registration) | GERON CORPORATION | 0000891618-96-000869 ↗ |
| 1996-06-26 | S-1/A | S-1/A (amendment) | GERON CORPORATION | 0000891618-96-001019 ↗ |
| 1996-07-18 | S-1/A | S-1/A (amendment) | GERON CORPORATION | 0000891618-96-001256 ↗ |
| 1996-07-26 | S-1/A | S-1/A (amendment) | GERON CORPORATION | 0000891618-96-001344 ↗ |
| 1996-07-30 | S-1/A | S-1/A (amendment) | GERON CORPORATION | 0000891618-96-001429 ↗ |
| 1996-07-31 | 424B4 | 424B4 (final prospectus) | GERON CORPORATION | 0000891618-96-001452 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 1996-07-30 | S-1/A | registration statement | $8.00–$10.00 | 2,500,000 | - | Nasdaq GERN | 7 | from the submission text; range, shares headline, cover names 7 | document ↗ | |
| 1996-07-31 | 424B4 | final prospectus | $8.00 | 2,000,000 | $16,000,000 | Nasdaq GERN | 7 | from the submission text; price sentence, shares headline, proceeds computed, underwriting table 6, cover names 3 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| BEHRS MELISSA KELLY | Director,Officer; Officer | EVP BD and Port&Alliance Mgmt; EVP BD, Port & Alliance Mgmt; EVP, BD, Port & Alliance Mgmt; EVP Chief Business Officer; EVP, Chief Business Officer; EVP Portfolio & Alliance Mgmt; SVP Alliance and Prog Mgmt; SVP Oncology; SVP Portfolio & Alliance Mgmt; SVP Strategic Portfolio Mgmt; VP, Oncology | 38 | 2006–2021 | |
| EARP DAVID | Officer | Chief Legal Counsel; SVP Bus Dev / Chf Patent Couns; SVP Bus Dev, Chief Patnt Couns; SVP, Chief Legal Officer; SVP, Corp Transactions | 18 | 2006–2012 | |
| GREENWOOD DAVID | Director,Officer; Officer; Other | EVP and CFO; Executive VP and CFO; President, Interim CEO, CFO | 22 | 2006–2012 | |
| HARLEY CALVIN | Officer | Chief Scientific Officer; VP and CSO; VP, CSO Telomerase Tech | 12 | 2006–2009 | |
| LEBKOWSKI JANE | Officer; Other | SVP, Chief Scientific Officer; SVP, CSO Regen Med; SVP, Regenerative Medicine; SVP Regen Medicine | 17 | 2006–2012 | |
| OKARMA THOMAS | Director,Officer; Officer | President and CEO | 14 | 2006–2010 | |
| BARKAS ALEXANDER E | Director | 11 | 2006–2011 | ||
| FRITZKY EDWARD V | Director | 14 | 2006–2013 | ||
| HOMCY CHARLES J | Director | 8 | 2006–2011 | ||
| KILEY THOMAS | Director | 14 | 2006–2013 | ||
| WALKER JOHN PETER | Director | 5 | 2006–2009 | ||
| ZENNER PATRICK J | Director | 7 | 2006–2010 | ||
| Colowick Alan | Officer | President, Oncology | 6 | 2006–2008 | |
| Benedetti Fabio M | Officer | SVP, Chief Med Off, Oncology | 5 | 2008–2009 | |
| Spink Katharine E. | Officer; Other | SVP Alliance Mgmt & Operations; SVP Prgm Mgmt, Cell Therapies; VP Operations, Regen Med Progs; VP Ops, Regen Med Programs | 11 | 2009–2012 | |
| EASTHAM KARIN | Director | 24 | 2009–2023 | ||
| Kelsey Stephen Michael | Officer | EVP, CMO, Oncology; EVP, R&D, Chief Med Officer; EVP, R&D Head, CMO | 15 | 2009–2013 | |
| Hofstaetter Thomas | Director | 13 | 2010–2015 | ||
| Huh Hoyoung | Director; Director,Officer | Executive Chairman | 22 | 2010–2018 | |
| Spiegel Robert J. | Director | 71 | 2010–2026 | ||
| Bloom Olivia Kyusuk | Officer | Controller, Chief Acctg Off; EVP, Chief Financial Officer; SVP, CFO and Treasurer; SVP, Chief Financial Officer; VP, Chief Acctg Officer | 26 | 2010–2023 | |
| Nallicheri Melanie I | Officer | SVP Corp Dev | 3 | 2011–2012 | |
| SCARLETT JOHN A | Director,Officer | Chairman, President and CEO; CHAIRMAN, PRESIDENT AND CEO; Chief Executive Officer; President and CEO; President, CEO and Chairman | 23 | 2011–2025 | |
| ROSENFIELD STEPHEN | Officer | EVP, Chief Legal Officer; EVP, Chief Legal Off & Sec; EVP, Genl Counsel & Secretary; Secretary | 15 | 2011–2022 | |
| COOPER GRAHAM K | Officer | EVP, Bus Dev & CFO | 3 | 2012 | |
| LAWLIS V BRYAN | Director | 18 | 2012–2025 | ||
| GRETHLEIN ANDREW J | Officer | EVP, Chief Operating Officer; EVP, CHIEF OPERATING OFFICER; EVP, Development &Tech Ops; EVP, Technical Operations; EVP, Tech Ops and Development | 19 | 2012–2025 | |
| BRADBURY DANIEL | Director | 16 | 2012–2019 | ||
| Molineaux Susan | Director | 42 | 2012–2026 | ||
| Parker Craig C | Officer | EVP, Corp Dev & Sci Affairs; SVP, Corporate Development | 3 | 2012–2014 | |
| Rizo Aleksandra | Officer | EVP, Chief Medical Officer | 5 | 2019–2022 | |
| Bir Dawn Carter | Director; Director,Officer | Interim President and CEO | 10 | 2019–2026 | |
| O'Farrell Elizabeth G. | Director | 13 | 2019–2026 | ||
| Kapur Anil | Officer | EVP, Corp Strategy & CCO; EVP, CORP STRATEGY & CCO | 11 | 2019–2024 | |
| Feller Faye | Officer | EVP, Chief Medical Officer; EVP, CHIEF MEDICAL OFFICER | 7 | 2022–2024 | |
| McDonald John F | Director | 6 | 2022–2026 | ||
| Samuels Scott Alan | Officer | EVP, Chief Legal Officer; EVP & CHIEF LEGAL OFFICER | 7 | 2023–2025 | |
| ROBERTSON MICHELLE | Officer | EVP, Chief Financial Officer; EVP, CHIEF FINANCIAL OFFICER | 6 | 2023–2026 | |
| Aggarwal Gaurav | Director | 5 | 2023–2025 | ||
| Ziegler James | Officer | EVP, Chief Commercial Officer | 4 | 2024–2025 | |
| Eid Joseph | Officer | EVP, R&D; Chief Medical Office; EVP, Research and Development | 3 | 2024–2026 | |
| Semerjian Harout | Director,Officer | President and CEO | 2 | 2025 | |
| ElNawawi Ahmed | Officer | EVP, Chief Commercial Officer | 2 | 2025 | |
| Andrews Patricia S | Director | 2 | 2026 | ||
| Chinoporos Constantine | Director | 2 | 2026 | ||
| Williams Timothy | Officer | EVP and Chief Legal Officer | 2 | 2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Plan sponsor | GERON CORPORATION | CA | Form 5500 (employee benefit plans) | EIN (EXACT) |
| SEC filer | GERON CORP | SEC filers (EDGAR) | CIK (EXACT) | |
| Business registration | FLORIDA GERON CORPORATION | State business registries | EIN (EXACT, as the state registration reports it) | |
| Business registration | Geron Corporation | State business registries | name and state | |
| Business registration | Geron Corporation | State business registries | name and state | |
| Business registration | Geron Corporation | State business registries | name and state | |
| Business registration | Geron Corporation | State business registries | name and state | |
| Business registration | GERON CORPORATION | State business registries | name and state | |
| Business registration | GERON CORPORATION | State business registries | name and state | |
| Business registration | GERON CORPORATION | State business registries | name and state | |
| Business registration | GERON CORPORATION | State business registries | name and state | |
| Form 5500 plan sponsor | GERON CORPORATION | EIN (EXACT) | ||
| Federal award recipient | GERON CORP | Federal spending (USAspending) | name and state | |
| Lobbying client | GERON CORP | Federal lobbying (LDA) | name and state |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.